Role of leukotrienes in antimicrobial host defense of the lung

Clinical Reviews in Allergy and Immunology

Volumn 17, Issue 1-2, 1999, Pages 261-269

  Peters Golden, Marc ^a   Coffey, Michael ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE; BIOLOGICAL RESPONSE MODIFIER; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANTIMICROBIAL ACTIVITY; HOST RESISTANCE; HUMAN; ICOSANOID METABOLISM; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; INHALATIONAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; LUNG ALVEOLUS MACROPHAGE; LUNG INFECTION; NEUTROPHIL; NONHUMAN; PNEUMONIA; REVIEW;

EID: 0032776410     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02737609     Document Type: Review

References (34)

1. Fels A, Cohn Z. The alveolar macrophage. J Appl Physiol 1986;60:353-369.
2. Toews G, Gross G, Pierce A. The relationship of innoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis 1979;120:559-567.
3. Baggiolini M, Walz A, Kunkel S. Neutrophil-activating peptide-I/interleukin b, a novel cytokine that activates neutrophils. J Clin Invest 1989;84:1045-1049.
4. Henderson W, Jr. Eicosanoids and lung inflammation. Am Rev Respir Dis 1987;135:1176-1185.
5. Hopkins H, Stull T, Von Essen S, Robbins R, Rennard S. Neutrophil chemotactic factors in bacterial pneumonia. Chest 1989;95:1021-1027.
6. Buret A, Dunkley M, Clancy R, Cripps A. Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: Role of neutrophils and leukotriene B4. InfectImmun 1993;61:671-679.
7. Bailie M, Standiford J, Laichalk L, Coffey M, Strieter R, Peters-Golden M. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J Immunol 1996;157:5221-5224.
8. Bigby T, Holtzman M. Enhanced 5-lipoxygenase activity in lung macrophages compared to monocytes from normal subjects. J Immunol 1987;138: 1546-1550.
9. Grimminger F, Sibelius U, Seeger W. Amplification of LTB4 generation in AM-PMN cocultures: Transcellular 5-lipoxygenase metabolism. Am J Physiol (Lung Cell Mol Physiol) 1991;261:L195-L203.
10. Chen X, Sheller J, Johnson E, Funk C. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994;372:179-182.
11. Coffey M, Phare S, Kazanjian P, Peters-Golden M. Reduced 5-lipoxygenase metabolism in alveolar macrophages from subjects infected with the human immunodeficiency virus. J Immunol 1996;157:393-399.
12. Coffey M, Phare S, George S, Peters-Golden M, Kazanjian P. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J Clin Invest 1998;102:663-670.
13. Hirschtick R, Glassroth J, Jordan M, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995;333: 845-851.
14. Limper A, Offord K, Smith T, Martin II W. Pneumocystis carinii pneumonia: Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989;140:1204-1209.
15. Krarup E, Vestbo J, Benfield T, Lundgren J. Interleukin-8 and leukotriene B4 in bronchoalveolar lavage fluid from HIV-infected patients with bacterial pneumonia. Respiratory Medicine 1997;91:317-321.
16. Watari K, Asamo S, Shirafuji N, et al. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 1989;73:117-122.
17. Mauss S, Steinmetz H, Willers R, et al. Induction of granulocyte colonystimulating factor by acute febrile infection but not by neutropenia in HIV-seropositive individuals. J AIDS Human Retrovirol 1997;14:430-434.
18. Nelson S, Farkas S, Fotheringham N, Ho H, Marrie T, Movahhed H. Filgrastim in the treatment of hospitalized patients with community acquired pneumonia. Am J Respir Crit Care Med 1996;153S:A535.
19. Jubiz W, Draper R, Gale J, Nolan G. Decreased leukotriene B4 synthesis by polymorphonuclear leukocytes from male patients with diabetes mellitus. Prostaglandins Leukotrienes Med 1984;14:305-311.
20. Greco N, Milks M, Panganamala R. Metabolism of arachidonic acid in neutrophils from alloxan-diabetic rabbits. Prostaglandins Leukotrienes Essential Fatty Acids 1990;42:201-208.
21. Coffey M, Wilcoxen S, Simpson R, Phare S, Gyetko M, Peters-Golden M. Reduced 5lipoxygenase metabolism in macrophages from 1,25-dihydroxy-vitamin D3-deficient rats. Prostaglandins 1994;48:313-329.
22. Lu M-C, Hostetler D, Robinson N, Derksen F, Peters-Golden M. Age-related increases in 5-lipoxygenase activity of cattle alveolar macrophages. Am J Physiol (Lung Cell Mol Physiol) 1995;271:L547-554.
23. Skerrett S, Henderson W, Martin T. Alveolar macrophage function in rats with severe protein calorie malnutrition: Arachidonic acid metabolism, cytokine release, and antimicrobial activity. J Immunol 1990;144:1052-1061.
24. Serhan CN, Radin A, Smolen JE, Korchak H, Samuelsson B, Weissmann G. Leukotriene B4 is a complete secretagogue in human neutrophils. Biochem Biophys Res Commun 1982;107:1006-1012.
25. O'Flaherty J, Redman J, Jacobson D. Mechanisms involved in the bidirectional effect of PKC activation on neutrophil responses to leukotriene B4. J Immunol 1990;144:1909-1913.
26. Wijkander J, O'Flaherty J, Nixon A, Wykle R. 5-Lipoxygenase products modulate the activity of the 85-kDa phospholipase A2 in human neutrophils. J Biol Chem 1995;270:26,543-26,549.
27. Martin TR, Pistorese BP, Chi KY, Goodman RB, Matthay MA. Effect of leukotriene B4 in the human lung: Recruitment of neutrophils into the alveolar spaces without a change in protein permeability. J Clin Invest 1989;89:1009-1019.
28. Marder P, Sawyer J, Froelich L, Mann L, Spaethe S. Blockade of human neutrophil activation by 2- [2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY29311), a novel leukotriene B4 receptor antagonist. Biochem Pharmacol 1995;49:1683-1690.
29. Strieter R, Kasahara K, Allen R, et al. Cytokine-induced neutrophil-derived interleukin-8. Am J Pathol 1992;141:397-407.
30. Rhodes J, Salmon J, Wood J. Macrophage Fcγ2b receptor expression and receptor-mediated phospholipase activity: Regulation by endogenous eicosanoids. Eur J Immunol 1985;15:222-227.
31. Peppelenbosch M, Tertoolen L, Hage W, de Laat S. Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products. Cell 1993;74:565-575.
32. Hubbard N, Erickson K. Role of 5-lipoxygenase metabolites in the activation of peritoneal macrophages for tumoricidal function. Mol Immunol 1995;160:115-122.
33. Demitsu T, Katayama H, Saito-Taki T, Yaoita H, Nakano M. Phagocytosis and bactericidal action of mouse peritoneal macrophages treated with leukotriene B4. Int J Immunopharmacol 1989;11:801-808.
34. Sampson S, Costello J, Sampson A. The effect of inhaled leukotriene B4 in normal and in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1789-1792.